⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
Rybrevant (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
JNJ
HALO
Zabdeno (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
JNJ
Tecvayli (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
JNJ
Bladder Cancer Patients Report Delayed Diagnosis and Gaps in Support
globenewswire.com
JNJ
FER
URGN
Pharmaceuticals, Biotechnology and Diagnostics M&A Agreements Report/Directory 2026: Analyse 2,500+ Deals Signed Since 2021 - Company A-Z, Therapeutic Area, Technology Type, and Industry Segment
globenewswire.com
JNJ
NVS
EcoVadis and Watershed partner to close the Scope 3 data gap
prnewswire.com
JNJ
JPM
FDX
V
Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia
globenewswire.com
MRK
JNJ
GOOG
Demande d’autorisation de mise sur le marché de TECVAYLI®▼ (teclistamab) en monothérapie soumise à l’EMA pour le myélome multiple en rechute ou réfractaire après au moins une ligne de traitement antérieure
globenewswire.com
JNJ
Antrag bei der EMA für die TECVAYLI®▼ (teclistamab)-Monotherapie zur Behandlung des rezidivierten/refraktären multiplen Myeloms nach mindestens einer vorherigen Therapie eingereicht
globenewswire.com
JNJ
BioGene Therapeutics Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director Ready to Announce with Confidence?
newsfilecorp.com
RLMD
JNJ